888-296-8858 Contact Us Search Link
Search Website Submit Search
PROKERA®
AmnioGraft®
AmnioGuard®
Cliradex®
Regulatory & Quality
Medical Inquiries
PROKERA for Patients
AmnioGraft for Patients
AmnioGuard for Patients
Clinical Results of Using Amniotic Membrane-Umbilical Cord Graft for Reducing Glaucoma Shunt Tube Exposure Published in Ophthalmology Glaucoma Journal
Miami, FL – December 10, 2019 – Bio-Tissue, Inc., a TissueTech, Inc. company and leader in the clinical application of amniotic membrane and umbilical cord birth tissue products for unmet patient needs, announced today that the results from a clinical study on the use of amniotic membrane – umbilical cord grafts have been published in Ophthalmology Glaucoma, the peer-reviewed publication for the American Academy of Ophthalmology® in partnership with the American Glaucoma Society.
Bio-Tissue Launches Website to Educate on Long-Lasting Solution for Mechanical Dry Eye (MDE), aka Conjunctivochalasis (CCh)
Miami, FL – November 12, 2019 – Bio-Tissue, Inc., a TissueTech, Inc. company and leader in the clinical application of amniotic membrane and umbilical cord-based products for unmet patient needs, announced today the launch of an educational website, www.DiscoverMDE.com , on Mechanical Dry Eye, MDE, also sometimes referred to as Conjunctivochalasis (CCh). The website features educational information, videos, testimonials and other resources for both patients and health care providers.
Bio-Tissue Founder, Pioneer in Ocular Use of Amniotic Membrane Mentors Minority Students During 2019 American Academy of Ophthalmology Meeting
Miami, FL – November 4, 2019 – Scheffer C.G. Tseng, MD, PhD, Chief Technology Officer and co-founder of Bio-Tissue, Inc., a TissueTech company, shared insights with underrepresented undergraduates and medical students about the rewards and opportunities of studying ophthalmology during their residencies at this year's Minority Ophthalmology Mentoring Program on October 13, 2019 at the American Academy of Ophthalmology's annual meeting in San Francisco.
TissueTech Names New Vice President to Lead Human Resources Operations and Process Improvement Initiatives
Miami, FL – October 2, 2019– TissueTech,™ Inc., a pioneer and market leader in the development and clinical application of human birth tissue products, today announced the appointment of Kim Tripodo to the role of Vice President of Human Resources. In this role, Ms. Tripodo will be responsible for all aspects of human resource functions and employee-related initiatives.
TissueTech Names New Vice President to Oversee Scale Up of Product Lifecycle Management and Technology Transfer Activities
Miami, FL – September 23, 2019– TissueTech™, Inc., a pioneer in the development and clinical application of regenerative human birth tissue products, today announced the appointment of Jerry Chang, PhD to the position of Vice President of Product Development. In this new role, Dr. Chang will have oversight for ensuring the efficiency and integrity of all Product Lifecycle Management activities and will control the processes and testing of biological products for human use as the Company moves closer to commercialization of its birth tissue products as biologics.
Bio-Tissue Expands National Footprint, Ramps Up Sales Force by More than 25 Percent
Miami, FL – September 11, 2019 – Bio-Tissue®, Inc., a TissueTech,™ Inc. company, and pioneer and market leader in the development and clinical application of Cryopreserved Amniotic Membrane (CAM) products for ocular surface disease and injury, today announced the expansion of its sales force to more effectively meet the needs of clinicians and their patients.
TissueTech Appoints New Vice President to Drive Assurance Strategy for all Product Development and Manufacturing Activities
Miami, FL – September 5, 2019 – TissueTech™, Inc., a pioneer in the development and clinical application of regenerative human birth tissue products, today announced the appointment of Sherry Saurini to the position of Vice President of Quality Assurance. In her new role, Ms. Saurini will have oversight for ensuring that the company is maintaining set requirements for the manufacture of birth tissue products for human use as the company moves closer to commercialization as a biologics provider.
TissueTech Expands its Clinical Program with Medidata's End-to-end Unified Platform
Miami, Fla. – July 3, 2019 – Medidata announced that TissueTech, Inc.. has chosen the Medidata Rave Clinical Cloud™ as its end-to-end platform for clinical trials. TissueTech recognizes this partnership as critical to helping spearhead the company's transformation in biologics with a focus on regenerative therapies derived from human birth tissue for patients with serious unmet clinical needs.
TissueTech Raises $82 million in latest round of equity financing
Miami, Fla. – June 26, 2019 – TissueTech, Inc., the pioneer in regenerative medicine utilizing human umbilical cord and amniotic membrane, today announced the closing of an $82.25 million round of Preferred C equity financing led by EW Healthcare Partners (formerly Essex Woodlands) and followed by the third round of continuous investments from Ballast Point Ventures.
Dr. Mark S. Milner to Present on Cryopreserved Amniotic Membrane at 2019 American Society of Cataract and Refractive Surgery (ASCRS)
Miami, Fla. – May 2, 2019 – Bio-Tissue, Inc., a TissueTech™, Inc. company and the market leader in the clinical application of cryopreserved amniotic membrane-based products for the treatment of diseases and disorders of the ocular surface, today announced that Mark S. Milner, M.D., FACS, Associate Clinical Professor at Yale University Medical School and Co-founder and Co-medical Director of Precision LASIK Group, will present about his use of Cryopreserved Amniotic Membrane to Treat Ocular Surface Diseases on Monday, May 6, during the Industry Spotlight Theater at the 2019 ASCRS•ASOA Annual Meeting.
Bio-Tissue, Inc. Highlights Publication of DREAM Study
MIAMI–(BUSINESS WIRE)–Bio-Tissue, Inc., a TissueTech, Inc. company, highlighted the publication of the Dry Eye Amniotic Membrane (DREAM) study in Clinical Ophthalmology.*
Bio-Tissue Announces Study that Demonstrates Cryopreserved Amniotic Membrane Graft Reduces Recurrence After Pterygium Surgery
MIAMI, November 27, 2017 – Bio-Tissue, Inc.®, a business unit of TissueTech™, Inc., announced today study findings, published in Cornea, 2017, show that the use of cryopreserved amniotic membrane reduces recurrence rates after pterygium surgery.
7300 Corporate Center Dr Suite 700
info@tissuetech.com
Copyright © 2020 Bio-Tissue. All Rights Reserved. Website Design by Web.com
Sitemap | Privacy Policy | Terms of Use
Submit a request to exercise your privacy consumer rights.	Privacy Policy
privacy@tissuetechinc.com
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We may use cookies, beacons (also known as pixels), and other similar technologies (together "cookies) to offer you a better experience, and analyze usage. By continuing to use this application, you consent to the use of cookies in accordance with our Privacy Policy.Ok